ABEONA THERAPEUT. DL-01 (PCJ) - Total Assets
Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) holds total assets worth €219.57 Million EUR (≈ $256.70 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
ABEONA THERAPEUT. DL-01 - Total Assets Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's total assets have evolved over time, based on quarterly financial data. Also see ABEONA THERAPEUT. DL-01 market capitalisation for the company's overall valuation and market capitalisation.
ABEONA THERAPEUT. DL-01 - Asset Composition Analysis
Current Asset Composition (December 2025)
ABEONA THERAPEUT. DL-01's total assets of €219.57 Million consist of 93.3% current assets and 6.7% non-current assets. Review ABEONA THERAPEUT. DL-01 debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 35.7% |
| Accounts Receivable | €6.15 Million | 2.8% |
| Inventory | €5.49 Million | 2.5% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABEONA THERAPEUT. DL-01's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ABEONA THERAPEUT. DL-01 stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABEONA THERAPEUT. DL-01's current assets represent 93.3% of total assets in 2025, an increase from 70.7% in 2021.
- Cash Position: Cash and equivalents constituted 35.7% of total assets in 2025, down from 41.4% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 2.8% of total assets.
ABEONA THERAPEUT. DL-01 Competitors by Total Assets
Key competitors of ABEONA THERAPEUT. DL-01 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
ABEONA THERAPEUT. DL-01 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.93 | 6.08 | 6.12 |
| Quick Ratio | 6.74 | 6.08 | 6.12 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €175.34 Million | €84.27 Million | €94.23 Million |
ABEONA THERAPEUT. DL-01 - Advanced Valuation Insights
This section examines the relationship between ABEONA THERAPEUT. DL-01's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.01 |
| Latest Market Cap to Assets Ratio | 1.29 |
| Asset Growth Rate (YoY) | 101.6% |
| Total Assets | €219.57 Million |
| Market Capitalization | $283.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values ABEONA THERAPEUT. DL-01's assets above their book value (1.29x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: ABEONA THERAPEUT. DL-01's assets grew by 101.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual total assets of ABEONA THERAPEUT. DL-01 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €219.57 Million ≈ $256.70 Million |
+101.57% |
| 2024-12-31 | €108.93 Million ≈ $127.35 Million |
+70.20% |
| 2023-12-31 | €64.00 Million ≈ $74.83 Million |
-0.33% |
| 2022-12-31 | €64.21 Million ≈ $75.07 Million |
-19.31% |
| 2021-12-31 | €79.59 Million ≈ $93.04 Million |
-- |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more